Raymond James analyst Andrew Cooper lowered the firm’s price target on Revvity (RVTY) to $140 from $146 and keeps an Outperform rating on the shares. The firm is taking a modestly conservative tack on the recovery ramp for Life Sciences Tools & Services through 2025 as well as layering in a substantially more significant foreign exchange headwind given movement in the dollar since Q3 results, the analyst tells investors in a research note. Revvity is the firm’s favorite of the group, which remains underappreciated in terms of strength of the base that should allow for another year at or near the front of the pack on organic growth.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Early notable gainers among liquid option names on January 13th
- Revvity, Element Biosciences collaborate to commercialize IVD solution
- Revvity to Announce Q4 and Full-Year 2024 Results
- Revvity receives FDA clearance for free testosterone immunoassay test
- Revvity downgraded to Market Perform from Outperform at Bernstein